Save up -80% on Peginterferon alfa-2a
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Pegasys
|$1,019.68||1 vial (1ml) 180mcg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Pegasys coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Peginterferon alfa-2a every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Peginterferon alfa-2a volume of distribution
Peginterferon alfa-2b has a relatively rapid absorption with a half-life of 4.6 hours and a volume of distribution of 0.99L/Kg, which are not significantly different from that of standard interferon alfa-2b, 2.3 hours and ~1.4L/Kg respectively.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Peginterferon alfa-2a
Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethylene glycol (PEG) chain. The PEG moiety is linked at a single site to the interferon alfa moiety via a stable amide bond to lysine. Peginterferon alfa-2a has an approximate molecular weight of 60,000 daltons. Interferon alfa-2a is produced using recombinant DNA technology in which a cloned human leukocyte interferon gene is inserted into and expressed in Escherichia coli. The resultant protein is 165 amino acids. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.
Peginterferon alfa-2a mechanism of action
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
Dosage forms of Peginterferon alfa-2a
|Injection, solution||subcutaneous||135 ug/.5mL|
|Injection, solution||subcutaneous||180 ug/mL|
|Injection, solution||subcutaneous||180 ug/.5mL|
Hoffmann La Roche Limited
Humans and other mammals
Indication of Peginterferon alfa-2a
For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi’s sarcoma.
Toxicity of Peginterferon alfa-2a
Pegasys suppresses bone marrow function and may result in severe cytopenias. Very rarely alpha interferons may be associated with aplastic anemia. It is advised that complete blood counts (CBC) be obtained pre-treatment and monitored routinely during therapy.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Peginterferon alfa-2a on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.